subject: Aarkstore Enterprise---indian Diabetes Market Report & Outlook For 2010-2015 [print this page] With around 51 Million diabetes patients, India promises to be amongst the most lucrative diabetes markets in the world. In 2009, the total sales of Insulin and Non-Insulin Anti-diabetics reached US$ 424 Million. Although, this represents just a fraction of the global sales, IMARC expects this market to surge in the future.
In 2009, Non-Insulin Anti-diabetics occupied 72% of the total diabetes market. Biguanides represented the leading drug class with a 43% market share. In the next five years, IMARC expects newer classes such as DPP-IV Inhibitors and GLP-1 Agonists to drive the Non-Insulin Anti-diabetics market. From a market share of 6% in 2009, IMARC expects DPP-IV Inhibitors to occupy 17% of the total Non-Insulin Anti-diabetics market by 2015.
Unlike Non-Insulins, the Insulin market in India was concentrated with the top five players occupying 96% of the total market. The Insulin market is expected to grow at a CAGR of 25% between 2010 and 2015, registering sales worth US$448 Million. During the next five years, the main drivers of this market will be the growth in the total drug treated population coupled with a much improved access and administration of Insulin.
Report Highlights
*
A growing drug treated population coupled with the launch of several new drugs will drive the Indian diabetes market to US$1.4 Billion by 2015.
*
In 2009, the market for Non-Insulin Anti-diabetics was worth US$ 306 Million. This represented a highly fragmented market with USV being the leading player with a 14% share.
*
USVs Glycomet GP (Glimepiride+Metformin) was the leading drug in the Non-Insulin Anti-diabetics market with sales worth nearly US$ 10.5 Million
*
IMARC expects around 15 new Drugs to be launched in the Non-Insulin Anti-diabetics market in the next five years. Seven of them are expected to be in the DPP-IV Inhibitor and GLP-1 Agonist classes.
*
The Insulin Market was worth US$ 117 Million in 2009. Abbott was Indias biggest player accounting for 61% of the total sales.
*
Sanofi Aventis Lantus (Insulin Glargine) represented one of the fastest growing drugs in the last five year and registered sales worth nearly 11 Million in 2009
*
The total number of diabetes patients in India is expected to reach 87 Million by 2030. Around 56% of these patients will be from urban regions.
